ProPhase Labs, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
ProPhase Labs, Inc. (PRPH) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $2.00 thousand as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2020-03-26
- 2019-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $2.00K.
- 2019-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $6.00K.
- 2019-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $1.00K.
- 2019-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $9.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2019-12-31 | $2.00K 10-K · filed 2020-03-26 |
| 2019-09-30 | $6.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $9.00K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $24.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $24.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $53.00K 10-Q · filed 2018-08-20 |
| 2018-03-31 | $121.00K 10-Q/A · filed 2018-08-20 |
| 2017-12-31 | $78.00K 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |